查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲急性症候群檢測市場 - 分析與預測（2023-2033）
市場調查報告書
商品編碼
1393907

歐洲急性症候群檢測市場 - 分析與預測（2023-2033）

Europe Acute Care Syndromic Testing Market - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 110 Pages | 商品交期: 1-5個工作天內

價格

2022年歐洲急性症候群檢測市場規模為9億美元，預計2023年至2033年年複合成長率為8.95%，到2033年達到23.2億美元。

分子診斷技術（例如症候群組）可以同時檢測多種病原體。這些病原體通常表現出類似或重疊的臨床症狀，使患者管理更容易，特定病症的診斷更容易。

主要市場統計資料
預測期 2023-2033
2023年評估值 9.8億美元
2033年預測 23.2億美元
年複合成長率 8.95%

由於對感染疾病早期檢測的需求不斷增加，歐洲急性綜合症檢測行業經歷顯著的快速成長。大流行的爆發和感染疾病的傳播對該成長做出了重大貢獻。此外，全球氣溫上升以及各地新感染疾病的發現也支持了該產業的擴張。

歐洲急性綜合症檢測領域提供了有前景的醫療保健解決方案，並且預計將進一步發展。由於傳染病早期檢測、治療計劃、診斷和監測設備的進步，感染疾病護理綜合症檢測市場不斷成長。歐洲市場對醫療基礎設施的投資不斷增加，先進診斷技術的採用也不斷增加，進一步推動了急性照護症候群檢測市場的成長。此外，還有有利的法規和舉措促進將症候群小組測試涵蓋常規臨床實踐。

本報告考察了歐洲急性綜合症檢測市場，提供了市場概述、最終用戶、國家/地區的趨勢以及參與市場的公司概況。

目錄

第1章 市場

  • 產品定義
  • 涵蓋與排除標準
  • 市場範圍
  • 調查方法

第2章 市場概況

  • 概述
  • 急性護理症候群檢測的工作流程分析
  • 市場足跡和成長潛力
  • 未來性

第3章 業界考察

  • 相關利益者觀點（N=20）
    • 醫生的觀點
    • 付款人的觀點
    • 投資者的觀點
  • 急性護理綜合症檢測市場的法律和法律規範
    • 北美法規結構
    • 歐洲法規結構
    • 亞太地區法規結構
    • 拉丁美洲法規結構
    • 其他地區的法律規範
  • 產品基準評效

第4章 市場動態

  • 概述
  • 影響分析
  • 市場促進因素
  • 市場挑戰
  • 市場機會

第5章 歐洲

  • 概述
  • 歐洲
    • 歐洲急性症候群檢測市場，依最終用戶分類
    • 歐洲急性症候群檢測市場，依國家

第6章 公司簡介

  • 急性期症候群檢測市場參與企業
  • Biocartis NV
  • bioMerieux SA（BioFire Diagnostics）
  • DiaSorin SpA（Luminex Corporation）
  • Eurofins Scientific（Eurofins Viracor）
  • QIAGEN NV
  • QuantuMDx Group Ltd.
  • Siemens Healthineers AG
Product Code: BHP1596SS

“The Europe Acute Care Syndromic Testing Market Expected to Reach $2.32 Billion by 2033.”

Introduction to Europe Acute Care Syndromic Testing Market

The Europe acute care syndromic testing market was valued at $0.90 billion in 2022 and is expected to reach $2.32 billion by 2033, growing at a CAGR of 8.95% between 2023 and 2033. Molecular diagnostics techniques such as syndromic panels are capable of simultaneously detecting several pathogens. These pathogens typically exhibit comparable or overlapping clinical symptomatology, making patient management easier and specific symptom diagnosis more straightforward.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$0.98 Billion
2033 Forecast$2.32 Billion
CAGR8.95%

Market Introduction

The increasing demand for early infectious illness identification has led to a notable surge in the acute care syndromic testing industry in Europe. The incidence of pandemics and the prevalence of infectious diseases have been major contributors to this rise. Furthermore, the expansion of the industry has been aided by the rise in global temperatures and the discovery of new infectious diseases in different places.

Promising healthcare solutions are available in the European acute care syndromic testing sector, and more developments may be possible. The acute care syndromic testing market is growing as a result of the advancement of instruments for early detection, treatment planning, diagnosis, and monitoring of infectious diseases. The Europe market is witnessing increasing investments in healthcare infrastructure and the adoption of advanced diagnostic technologies, further boosting the growth of the acute care syndromic panel testing market. Additionally, favorable regulations and initiatives promoting the integration of syndromic panel testing in routine clinical.

Market Segmentation

Segmentation 1: by End User

  • Hospitals
  • Clinical and Diagnostic Laboratories
  • Research and Academic Institutions
  • Other End Users

Segmentation 2: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The Europe acute care syndromic testing market has been extensively segmented on the basis of various categories, such as end user and Country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the Europe acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

  • Biocartis NV
  • bioMerieux SA (BioFire Diagnostics)
  • DiaSorin S.p.A (Luminex Corporation)
  • Eurofins Scientific (Eurofins Viracor)
  • QIAGEN N.V.
  • QuantuMDx Group Ltd.
  • Siemens Healthineers AG

Table of Contents

1 Markets

  • 1.1 Product Definition
  • 1.2 Inclusion and Exclusion Criteria
  • 1.3 Market Scope
    • 1.3.1 Key Questions Answered in the Report
  • 1.4 Research Methodology
    • 1.4.1 Acute Care Syndromic Testing Market: Research Methodology
    • 1.4.2 Data Sources
      • 1.4.2.1 Primary Data Sources
      • 1.4.2.2 Secondary Data Sources
    • 1.4.3 Market Estimation Model
    • 1.4.4 Criteria for Company Profiling

2 Market Overview

  • 2.1 Overview
  • 2.2 Acute Care Syndromic Testing Workflow Analysis
  • 2.3 Market Footprint and Growth Potential
  • 2.4 Future Potential

3 Industry Insight

  • 3.1 Stakeholder's Perspective (N=20)
    • 3.1.1 Physician's Perception
    • 3.1.2 Payor's Perception
    • 3.1.3 Investor's Perception
  • 3.2 Legal and Regulatory Framework of the Acute Care Syndromic Testing Market
    • 3.2.1 Regulatory Framework in North America
      • 3.2.1.1 The U.S.
      • 3.2.1.2 Canada
    • 3.2.2 Regulatory Framework in Europe
    • 3.2.3 Regulatory Framework in Asia-Pacific
      • 3.2.3.1 Japan
      • 3.2.3.2 China
      • 3.2.3.3 India
      • 3.2.3.4 South Korea
      • 3.2.3.5 Australia
    • 3.2.4 Regulatory Framework in Latin America
      • 3.2.4.1 Brazil
      • 3.2.4.2 Mexico
    • 3.2.5 Regulatory Framework in Rest-of-the-World
      • 3.2.5.1 U.A.E.
      • 3.2.5.2 K.S.A.
  • 3.3 Product Benchmarking

4 Market Dynamics

  • 4.1 Overview
  • 4.2 Impact Analysis
  • 4.3 Market Drivers
    • 4.3.1 Faster Results Acquired with Syndromic Tests
    • 4.3.2 Increasing Incidence of Infectious Diseases
    • 4.3.3 Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
    • 4.3.4 Reduced Severe Adverse Effects from Pathogens
  • 4.4 Market Challenges
    • 4.4.1 Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
    • 4.4.2 Lack of High-Complexity Testing Centres
  • 4.5 Market Opportunities
    • 4.5.1 Quick Access to Treatment and Reduced Use of Antibiotics
    • 4.5.2 High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years

5 Europe

  • 5.1 Overview
  • 5.2 Europe
    • 5.2.1 Europe Acute Care Syndromic Testing Market, By End User
    • 5.2.2 Europe Acute Care Syndromic Testing Market, By Country
      • 5.2.2.1 Germany
      • 5.2.2.2 France
      • 5.2.2.3 U.K.
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest-of-Europe

6 Company Profiles

  • 6.1 Overview
  • 6.2 Acute Care Syndromic Testing Ecosystem Active Players
  • 6.3 Biocartis NV
    • 6.3.1 Company Overview
    • 6.3.2 Role of Biocartis NV in the Acute Care Syndromic Testing Market
    • 6.3.3 Financials
    • 6.3.4 Recent Developments
      • 6.3.4.1 Business Strategies
    • 6.3.5 Analyst Perspective
  • 6.4 bioMerieux SA (BioFire Diagnostics)
    • 6.4.1 Company Overview
    • 6.4.2 Role of bioMerieux SA (BioFire Diagnostics) in the Acute Care Syndromic Testing Market
    • 6.4.3 Financials
    • 6.4.4 Recent Developments
      • 6.4.4.1 Business Strategies
    • 6.4.5 Analyst Perspective
  • 6.5 DiaSorin S.p.A (Luminex Corporation)
    • 6.5.1 Company Overview
    • 6.5.2 Role of DiaSorin S.p.A (Luminex Corporation) in the Acute Care Syndromic Testing Market
    • 6.5.3 Financials
    • 6.5.4 Recent Developments
      • 6.5.4.1 Corporate Strategies
      • 6.5.4.2 Business Strategies
    • 6.5.5 Analyst Perspective
  • 6.6 Eurofins Scientific (Eurofins Viracor)
    • 6.6.1 Company Overview
    • 6.6.2 Role of Eurofins Scientific (Eurofins Viracor) in the Acute Care Syndromic Testing Market
    • 6.6.3 Financials
    • 6.6.4 Recent Developments
      • 6.6.4.1 Business Strategies
    • 6.6.5 Analyst Perspective
  • 6.7 QIAGEN N.V.
    • 6.7.1 Company Overview
    • 6.7.2 Role of QIAGEN N.V. in the Acute Care Syndromic Testing Market
    • 6.7.3 Financials
    • 6.7.4 Recent Developments
      • 6.7.4.1 Business Strategies
    • 6.7.5 Analyst Perspective
  • 6.8 QuantuMDx Group Ltd.
    • 6.8.1 Company Overview
    • 6.8.2 Role of QuantuMDx Group Ltd. in the Acute Care Syndromic Testing Market
    • 6.8.3 Recent Developments
      • 6.8.3.1 Corporate Strategies
      • 6.8.3.2 Business Strategies
    • 6.8.4 Analyst Perspective
  • 6.9 Siemens Healthineers AG
    • 6.9.1 Company Overview
    • 6.9.2 Role of Siemens Healthineers AG in the Acute Care Syndromic Testing Market
    • 6.9.3 Financials
    • 6.9.4 Analyst Perspective

List of Figures

  • Figure 1: Acute Care Syndromic Testing Market, $Billion, 2023 and 2033
  • Figure 2: History of Known Pandemics
  • Figure 3: Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
  • Figure 4: Acute Care Syndromic Testing Market (by Disease Type), Share (%), 2022 and 2033
  • Figure 5: Acute Care Syndromic Testing Market (by Target), Share (%), 2022 and 2033
  • Figure 6: Share of Acute Care Syndromic Testing Market (by Region), 2022
  • Figure 7: Share of Key Developments and Strategies, January 2020-June 2023
  • Figure 8: Acute Care Syndromic Testing Market (by Company), Share (%), 2022
  • Figure 9: Acute Care Syndromic Testing Market: Research Methodology
  • Figure 10: Primary Research Methodology
  • Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 12: Top-Down Approach (Segment-Wise Analysis)
  • Figure 13: Acute Care Syndromic Testing Workflow
  • Figure 14: Acute Care Syndromic Testing Market, $Billion, 2022-2033
  • Figure 15: Physician's Perception on the Factors Affecting the Adoption of Acute Care Syndromic Testing
  • Figure 16: Acute Care Syndromic Testing Market Dynamics
  • Figure 17: Traditional Testing vs. Syndromic Testing
  • Figure 18: Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
  • Figure 19: Incidence of Common Infectious Diseases in Germany (Excluding COVID-19), 2020
  • Figure 20: Incidence of Common Infectious Diseases in China, 2020
  • Figure 21: History of Known Pandemics
  • Figure 22: Examples of Cost Reductions
  • Figure 23: Time of Diagnosis vs. Disease Effect
  • Figure 24: Syndromic Panels Reimbursement Scenario in the U.S.
  • Figure 25: Syndromic Panels Reimbursement Scenario in Mexico
  • Figure 26: Reduction in Antibiotics Use with Syndromic Testing
  • Figure 27: Increasing Synergistic Activities of the Acute Care Syndromic Testing Market, January 2021-June 2023 (Number of Partnerships, Collaborations and Agreements)
  • Figure 28: Key Mergers and Acquisitions in the Acute Care Syndromic Testing Market
  • Figure 29: Acute Care Syndromic Testing Market Snapshot (by Region)
  • Figure 30: Acute Care Syndromic Testing Market (by Region), $Billion, 2022-2033
  • Figure 31: Europe Acute Care Syndromic Testing Market, $Billion, 2022-2033
  • Figure 32: Europe Acute Care Syndromic Testing Market (by End User), $Billion, 2023-2033
  • Figure 33: Europe Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
  • Figure 34: Top 5 Most Common Infectious Diseases in Germany, 2020
  • Figure 35: Germany Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 36: France Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 37: U.K. Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 38: Italy Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 39: Spain Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 40: Rest-of-Europe Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 41: Acute Care Syndromic Testing Market, Total Number of Companies Profiled
  • Figure 42: Biocartis NV: Product Portfolio
  • Figure 43: Biocartis NV: Overall Financials, $Million, 2020-2022
  • Figure 44: Biocartis NV: R&D Expenditure, $Million, 2020-2022
  • Figure 45: bioMerieux SA (BioFire Diagnostics): Product Portfolio
  • Figure 46: bioMerieux SA (BioFire Diagnostics): Overall Financials, $Million, 2020-2022
  • Figure 47: bioMerieux SA (BioFire Diagnostics): Revenue (by Segment), $Million, 2020-2022
  • Figure 48: bioMerieux SA (BioFire Diagnostics): Revenue (by Region), $Million, 2020-2022
  • Figure 49: bioMerieux SA (BioFire Diagnostics): R&D Expenditure, $Million, 2020-2022
  • Figure 50: DiaSorin S.p.A (Luminex Corporation): Product Portfolio
  • Figure 51: DiaSorin S.p.A (Luminex Corporation): Overall Financials, $Million, 2021 and 2022
  • Figure 52: DiaSorin S.p.A (Luminex Corporation): Revenue (by Region), $Million, 2021 and 2022
  • Figure 53: DiaSorin S.p.A (Luminex Corporation): R&D Expenditure, $Million, 2021 and 2022
  • Figure 54: Eurofins Scientific (Eurofins Viracor): Product Portfolio
  • Figure 55: Eurofins Scientific (Eurofins Viracor): Overall Financials, $Million, 2020-2022
  • Figure 56: Eurofins Scientific (Eurofins Viracor): Revenue (by Segment), $Million, 2020-2022
  • Figure 57: Eurofins Scientific (Eurofins Viracor): Revenue (by Region), $Million, 2020-2022
  • Figure 58: QIAGEN N.V.: Product Portfolio
  • Figure 59: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
  • Figure 60: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
  • Figure 61: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
  • Figure 62: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
  • Figure 63: QuantuMDx Group Ltd.: Product Portfolio
  • Figure 64: Siemens Healthineers AG: Product Portfolio
  • Figure 65: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
  • Figure 66: Siemens Healthineers AG: Revenue (by Segment), $Million, 2020-2022
  • Figure 67: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
  • Figure 68: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Acute Care Syndromic Testing Product Mapping Analysis (by Disease Type)
  • Table 2: Acute Care Syndromic Testing Market: Impact Analysis
  • Table 3: Key Questions Answered in the Report
  • Table 4: Product Benchmarking of Acute Care Syndromic Testing Panels
  • Table 5: Likert Scale
  • Table 6: Impact Analysis of Market Drivers
  • Table 7: Impact Analysis of Market Challenges
  • Table 8: Popular Assays and Their Turnaround Times
  • Table 9: Acute Care Syndromic Testing Ecosystem Active Players